The preoperative serum tumor markers were as follows: 6.4%, 17.0%, 4.7%, 40.4%, and 28.1% of patients had elevated levels of squamous cell carcinoma antigen (SCC), total prostate-specific antigen (TPSA), neuro-specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin fragment 19 (Cyfra21-1), respectively. The gene discussed is SERPINB3; the disease is neoplasm.